Fig. 4From: Development of a highly sensitive method for detection of FLT3D835YDetection of MRD by RFN-AS-PCR in an AML patient with FLT3D835Y. Blood DNA samples from an AML patient at initial diagnosis (AML11–1), in remission after treatment (AML11–2), and after relapse (AML11–3) were analyzed for FLT3D835Y using Sanger sequencing (a) and RFN-AS-PCR (b). Note that AML11–2 is FLT3D835Y-positive based on RFN-AS-PCR but negative according to Sanger sequencing. Ten additional FLT3D835Y-negative AML samples were analyzed in parallelBack to article page